ASOPRS 49TH ANNUAL FALL SCIENTIFIC SYMPOSIUM HILTON CHICAGO • OCTOBER 25-26, 2018 FOCUS ON FORGING THE FUTURE SYLLABUS GENERAL INFORMATION Continuing Medical Education ASOPRS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor the Continuing Medical Education (CME) for physicians. The American Society of Ophthalmic Plastic and Reconstructive Surgery designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Self-assessment CME credit may be claimed if the physician completes the self-assessment questionnaire at the end of the online meeting evaluation. Continuing Medical Education Mission Statement The purpose of the American Society of Ophthalmic Plastic and Reconstructive Surgery’s Continuing Medical Education (CME) program is to present oculofacial plastic surgeons with the highest quality learning opportunities in the areas of aesthetics, eyelid, lacrimal, and orbital diseases that promote positive change in physician performance or competence, thus enabling such physicians to maintain or improve the knowledge, skills, and professional performance needed to provide the best possible care for their patients. Ongoing assessment of the impact of the CME program is important in determining modifications to existing activities and the development of new activities. Specific expected results include increased knowledge across the ASOPRS community, a desire among practicing ophthalmologists to pursue lifelong learning, the refinement of already employed techniques or skills, and the application of new techniques or skills for the improvement of practice and patient care. Evaluations/CME Certificates A link to an evaluation will be provided to attendees via email. Please complete the evaluation in its entirety after the meeting. You will have an opportunity to print a CME certificate once you have completed the evaluation. Your feedback is carefully considered when planning future meetings. Thank you in advance for helping ASOPRS improve our Fall Scientific Symposium. Abstract Disclaimer Abstract information is published as submitted. 2 FINANCIAL DISCLOSURES As an accredited CME provider, ASOPRS is responsible for demonstrating that our CME educational programs are planned and presented independent of commercial influence. In accordance with the guidelines of the Accreditation Council for Continuing Medical Education (ACCME), ASOPRS requires disclosure of relevant financial interests or affiliations with corporate organizations of Abstract Reviewers (AR), Faculty (F), Moderators (M), Program Committee and CME Subcommittee Members (PC), YASOPRS Committee Members (Y) and all other individuals in control of content. Therefore, all individuals in control of content have been required to disclose financial relationships with commercial entities that provide products or services related to the content they are either presenting, moderating, or in control of planning. The ASOPRS CME Subcommittee has conducted a conflict of interest (COI) resolution process with anyone determined to have a relevant financial relationship, which may have included reviewing their presentation for indicators of integrity and absence of bias, and an agreement from faculty to keep their presentation free from commercial bias. All presentations have been reviewed for commercially biased information, balance, evidence-based, or other indicators of integrity. Every effort has been made to not assign moderators to sections of the program that may relate to any financial disclosure they have made. Planners with relevant financial disclosures were removed from making any decisions or having any influence over the programmatic content or COI resolution process, which may or does relate to their financial disclosure. If members of the Executive Committee took a position of influence over the content, they have not been allowed to suggest faculty or topics that may be related to a relevant financial disclosure. During the CME educational program, the moderators have been asked to identify situations in which a presenter does not uphold the agreement above, by bringing the potential bias to the attention of the audience at the conclusion of the speaker’s presentation. Meeting attendees may also bring their concerns of potential bias to the microphone during the Q&A portion of the session. ASOPRS is committed to transparency. The CME Subcommittee has determined that financial disclosures deemed to be relevant will be published in this Syllabus. If a financial relationship was deemed relevant, the COI process has been conducted and the conflict resolved. If through observation at the meeting, or meeting evaluations, any faculty is determined to have presented a biased lecture, and it wasn’t addressed at the time of the education, the CME Subcommittee will follow up in writing with the individual and may bar the individual from presenting at future meetings. Vinay Aakalu, MD Co-Author Provisional Patent, University of Illinois at Chicago – Patents / Royalty Mica Bergman, MD Presenter Poriferous, LLC – Patents / Royalty Michael Burnstine, MD Co-Author Poriferous, LLC – Patents / Royalty Harley Dresner Co-Author ZiftMedical – Equity Owner Bruno Fayet Co-Author FCI Ophthalmics – Patents / Royalty 3 FINANCIAL DISCLOSURES John P. Fezza, MD Presenter Allergan – Lecture Fees, Galderma – Lecture Fees, Merz – Other, Sente Skin Care – Lecture Fees, Visant Medical – Patents / Royalty Megan Francis-Sedlak Co-Author Horizon Pharma – Employee Peter Hilger Co-Author ZiftMedical – Equity Owner Robert Holt Co-Author Horizon Pharma – Employee Alon Kahana, MD Faculty, Co-Author, Genentech, Inc. – Consultant / Advisor and Grant Support, Stryker Corp. – Consultant / Thesis Committee Advisor and Lecture Fees Stephen Klapper, MD Abstract Reviewer AdOM Advance Optical Technologies Ltd. – Equity Owner Jill Melicher Larson, MD Presenter, Moderator Slack, Inc. – Patents / Royalty, Zift Medical – Equity Owner, Unifeye Vision Partners – Equity Owner Wendy Lee, MD Program Committee Allergan, Galderma, Merz, Ophthalmology Web, Mallinkrodt – Consultant / Advisor Julian D. Perry, MD Program Committee, Lacrimal Nanometer – Patent, Elsevier textbook – Royalty YASOPRS Committee, Faculty, Co-Author Jean-Marc Ruban Co-Author FCI Ophthalmics – Consultant / Advisor Eric Simso Co-Author ZiftMedical – Employee Michael Sun Presenter Provisional Patent, University of Illinois at Chicago – Patents / Royalty Allen VanBeek Co-Author ZiftMedical – Equity Owner Edward Wladis, MD Presenter, Thesis Bausch and Lomb – Consultant / Advisor, Praxis Biotechnology – Equity Owner, Fuze Committee Hub – Grant Support, National Rosacea Society – Grant Support, Valeant Pharmaceuticals – Consultant / Advisor, Lions Eye Foundation – Grant Support Charles Yu Co-Author Provisional Patent, University of Illinois at Chicago – Patents / Royalty Christopher Zoumalan, MD Presenter MD Medical Designs, Inc. – Equity Owner, Allergan, Inc. – Consultant / Advisor All other individuals in control of content have declared that they have no relevant financial disclosures, or, their financial disclosures have not been found relevant to the content. 4 YASOPRS EYE OPENERS – RAPID FIRE CASES AND PRESENTATIONS Thursday, October 25 7 – 8 am Moderators: Jill Melicher-Larson, MD and Behin Barahimi, MD 7 – 7:04 am Evaluation of the Lacrimal Sac Using Ultrasound Biomicroscopy Mai Takagi1,2, Masashi Mimura1,2, Tsunehiko Ikeda3, Bobby Korn4,5, Don Kikkawa4,5 1Department of Ophthalmology, Osaka Medical College, Osaka, Japan, 2Department of Ophthalmology, Kaisei Hospital, Osaka, Japan, 3Department of Ophthalmology, Kaiser Hospital, Osaka, Japan, 4UC San Diego Department of Ophthalmology, Division of Oculofacial Plastic and Reconstructive Surgery, La Jolla, California, United States of America, 5Division of Plastic Surgery, UC San Diego, La Jolla, California, United States of America Introduction: To evaluate lacrimal sac (LS) size and physiological movement using ultrasound biomicroscopy. Methods: This is an interventional observational study of normal sixteen subjects. All subjects underwent evaluation of lacrimal sac using ultrasound biomicroscope. The maximum horizontal diameter of deflated LS, inflated LS by injecting hydroxyethyl cellulose, and coefficient of the inflation of LS calculated from the values were measured as outcome. Statistical analysis using t-test and Spearman’s correlation analysis were performed to evaluate the relationship between the outcomes and variables as age, gender, and height. Results: 16 patients including 10 males and 6 females were studied. Average age was 33.2 ± 6.4 years old. Average diameter of inflated and deflated LS was 1.76±0.27mm and 1.94±0.33mm. Average coefficient of inflation was 9.96±10.2%. Age and the diameters of lacrimal sac tend to correlate negatively (deflated LS: R=-0.27, P=0.16; inflated LS: R=-0.35, P=0.05). The diameter of LS was significantly larger in males (Average diameter of deflated and inflated LS: 1.90mm and 2.12mm) than in females (Average diameter of deflated and inflated LS: 1.62mm and 1.76mm) (P=0.001). The diameter of LS was also significantly larger in tallers subject (deflated LS: R=0.58, P=0.0005; inflated LS: R=0.63, P<0.0001). Conclusions: The UD-8000 is a novel device to study the lacrimal drainage system. The lacrimal diameter tends to be smaller as patients age and is larger in males and taller patients. These